FACTS ABOUT HEMGENIX REVEALED

Range of suitable patients: CDEC discussed the uncertainty in the number of individuals with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some patients who will be categorised as acquiring delicate or moderate illness may have a severe bleedi